- ViroCell Biologics has successfully manufactured and delivered a retroviral vector for AvenCell’s investigational CAR-T therapy, AVC-203.
- AVC-203 is expected to enter a Phase I trial for relapsed/refractory B-cell lymphoma in H2/2025.
ViroCell Biologics, a viral vector CDMO focused on cell and gene therapy clinical trials, has announced the successful delivery of a retroviral vector to AvenCell Therapeutics for its allogeneic CAR-T programme. The vector will be used to manufacture AVC-203, a dual-targeted CD19/CD20 therapy for B-cell malignancies and autoimmune diseases.
The collaboration marks the first delivery in the partnership between the two companies. AvenCell selected ViroCell based on its expertise in high-yield, rapid vector production. The CDMO incorporated a cell line provided by AvenCell into the GMP process to meet an accelerated delivery timeline.
AVC-203 is AvenCell’s second investigational cell therapy using its proprietary allogeneic engineering platform. The therapy is designed to address common limitations of CAR-T treatments by avoiding graft-versus-host disease and enhancing antigen targeting using its RevCAR™ receptor technology.
“We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform,” said John W. Hadden II, CEO of ViroCell. “I am proud of Team ViroCell’s accomplishments on the successful end-to-end delivery of this retroviral vector.”
AvenCell plans to begin a first-in-human Phase I study of AVC-203 in patients with relapsed or refractory B cell lymphoma in the second half of 2025.
